Unterberg A, Wahl M, Baethmann A
J Cereb Blood Flow Metab. 1984 Dec;4(4):574-85. doi: 10.1038/jcbfm.1984.82.
The effect of bradykinin on the permeability and vasomotor response of pial vessels has been studied to enhance our understanding of the pathophysiological role of the kallikrein-kinin system in cerebral tissue. Intravital fluorescence microscopy of the pia arachnoidea was conducted using Na+-fluorescein, FITC-dextran, and FITC-albumin as low and high molecular weight blood-brain barrier indicators. Massive arterial dilatation evolved immediately upon administration of bradykinin by superfusion of the exposed cerebral surface. An increase of the arterial diameter by 40% was the maximal response found at bradykinin concentrations of 4 x 10(-5) M. Arterial dilatation became attenuated with continuous superfusion of the preparation with bradykinin. In pial veins, a moderate reduction of the vessel diameter was observed, however, only after prolonged superfusion of the preparation. Bradykinin led to selective opening of the blood-brain barrier for Na+-fluorescein at superfusate concentrations of greater than or equal to 4 x 10(-7) M, but not for FITC-dextran or FITC-albumin. Topical administration of l-isoproterenol (10(-4) M) was found to prevent extravasation of Na+-fluorescein in the presence of bradykinin concentrations of 4 x 10(-6) M. Protection of the blood-brain barrier by isoproterenol was not observed when higher concentrations of bradykinin were employed. Intracarotid infusion of bradykinin were employed. Intracarotid infusion of bradykinin led also to a selective opening of the blood-brain barrier for Na+-fluorescein, but not for FITC-dextran or FITC-albumin. In contrast to superfusion, this route of administration did not induce changes of the vasomotor behavior of the arteries or veins. Additional experiments with B1-agonists and -antagonists suggest that bradykinin causes the openings of the blood-brain barrier th rough an interaction with B2-receptors on endothelial cells, and arterial dilatation via interaction with B2-receptors on vascular smooth muscle cells. Our findings support the concept that the release of kinins in the brain during an acute cerebral lesion mediates secondary damaging processes by the enhancement of blood-brain barrier dysfunction.
为了加深我们对激肽释放酶-激肽系统在脑组织中的病理生理作用的理解,研究了缓激肽对软脑膜血管通透性和血管舒缩反应的影响。使用Na + -荧光素、异硫氰酸荧光素-葡聚糖和异硫氰酸荧光素-白蛋白作为低分子量和高分子量血脑屏障指标,对软脑膜蛛网膜进行活体荧光显微镜检查。通过对暴露的脑表面进行灌流给予缓激肽后,立即出现大量动脉扩张。在缓激肽浓度为4×10(-5)M时,动脉直径增加40%是最大反应。随着缓激肽持续灌流制剂,动脉扩张减弱。在软脑膜静脉中,仅在制剂长时间灌流后观察到血管直径适度减小。缓激肽在灌流液浓度大于或等于4×10(-7)M时导致血脑屏障对Na + -荧光素选择性开放,但对异硫氰酸荧光素-葡聚糖或异硫氰酸荧光素-白蛋白则不然。发现局部给予l-异丙肾上腺素(10(-4)M)可在缓激肽浓度为4×10(-6)M时防止Na + -荧光素外渗。当使用更高浓度的缓激肽时,未观察到异丙肾上腺素对血脑屏障的保护作用。采用颈内动脉注射缓激肽。颈内动脉注射缓激肽也导致血脑屏障对Na + -荧光素选择性开放,但对异硫氰酸荧光素-葡聚糖或异硫氰酸荧光素-白蛋白则不然。与灌流不同,这种给药途径未引起动脉或静脉血管舒缩行为的改变。用B1激动剂和拮抗剂进行的额外实验表明,缓激肽通过与内皮细胞上的B2受体相互作用导致血脑屏障开放,并通过与血管平滑肌细胞上的B2受体相互作用引起动脉扩张。我们的研究结果支持这样的概念,即急性脑损伤期间脑中激肽的释放通过增强血脑屏障功能障碍介导继发性损伤过程。